Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbott, Injeq.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Lexicon, Mesoblast, Xeris.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Immunovant.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Siemens Healthineers.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ascentage, Beyondspring, Bionomics, Bioxcel, CTI, Cytodyn, Harmony, Huyabio, Innovent, Merck, Moleculin, Ridgeback, Shenzhen Chipscreen, Secura, Siga, Statera, Surface, Telix, VBI, Zogenix.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Paragon 28.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amylyx, Janssen, Nrx, RDIF, Statera, Tryp.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Nobel Biocare.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amniotics, Astrazeneca, Cstone, Daiichi, Leo, Novavax, Regor.

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Bioartic, Biogen, Biontech, Cstone, Daiichi Sankyo, Eirgenix, Eisai, Everest, Gilead, I-Mab, Innovent, Lianbio, Lion TCR, Merck, Moderna, Novavax, Pfizer, Providence, Sandoz, Takeda, Telix, Vaxine, Zogenix.